Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro- 2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma

Cancer

Volumn 117, Issue 19, 2011, Pages 4452-4459

  Wang, Wen Yi ^a   Twu, Chih Wen ^b,c   Lin, Wan Yu ^c   Jiang, Rong San ^c   Liang, Kai Li ^c   Chen, Kuan Wen ^c   Wu, Ching Te ^c   Shih, Yi Ting ^c   Lin, Jin Ching ^b,c,d  

^a HUNGKUANG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

18F fluoro 2 deoxy D glucose; Epstein Barr virus; nasopharyngeal carcinoma; positron emission tomography; quantitative polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; VIRUS DNA;

ADULT; AGED; ARTICLE; ASSAY; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PLASMA EPSTEIN BARR VIRUS DNA ASSAY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL RATE; YOUNG ADULT;

EID: 80052941434     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26069     Document Type: Article

References (22)

1. Chang JTC, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2006; 62: 501-507.
2. 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol. 2008; 81: 291-298. (Pubitemid 351702957)
3. 18F Fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24: 599-604. (Pubitemid 46630422)
4. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007; 48: 1614-1619. (Pubitemid 47572708)
5. Chua MLK, Ong SC, Wee JTS, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck. 2009; 31: 346-354.
6. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009; 36: 12-22.
7. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 1307-1314.
8. 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. J Nucl Med. 2006; 47: 1447-1454.
9. 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005; 46: 405-410.
10. 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2006; 33: 1032-1040.
11. Comoretto M, Balestreri L, Borsatti E, et al. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology. 2008; 249: 203-211.
12. 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004; 45: 1669-1676.
13. 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med. 2005; 46: 770-774.
14. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470. (Pubitemid 38736543)
15. Lo YMD, Chan LYS, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188-1191. (Pubitemid 29136244)
16. Twu CW, Wang WY, Liang WM, et al. Comparison the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007; 67: 130-137.
17. Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60: 6878-6881. (Pubitemid 32059157)
18. Chan ATC, Lo YMD, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94: 1614-1619. (Pubitemid 35378726)
19. Leung SF, Chan ATC, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003; 98: 288-291. (Pubitemid 36828452)
20. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006; 24: 5414-5418. (Pubitemid 46623174)
21. 18F-FDG PET in oncology. J Nucl Med. 2008; 49: 480-508. (Pubitemid 351355215)
22. Makitie AA, Reis PP, Irish J, et al. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck. 2004; 26: 815-822. (Pubitemid 39159305)